NXP100 beat eculizumab decisively in PNH with two filed MAAs in China, but Ex-China rights are licensed-in and NMPA approval determines whether the bet pays off

Bull

NMPA grants approval for NXP100 in treatment-naive PNH, validating the Phase 3 response rate of 59.5% versus eculizumab's 8.3% as a clinically and regulatorily meaningful superiority margin. Approval would establish NXP100 as a first-in-class oral Factor B inhibitor in China's PNH market, de-risk the Ex-China licensing strategy, and position Nuvectis to pursue regulatory filings in additional markets on the strength of the same dataset.

Bear

NMPA could issue a complete response requiring additional data, raise questions about the single-center or ethnically homogeneous trial design, or request longer-term durability and safety follow-up before granting approval, materially delaying commercialization. The most likely failure modes are regulatory requests for additional pharmacovigilance data, labeling disputes around the response endpoint definition, or manufacturing/CMC deficiencies in the MAA package — none of which are reflected in the clean Phase 3 efficacy readout.